Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Leukemia Clinical Trial

Official title:

An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Target Total Therapy for Adult Ph-like Acute Lymphoblastic Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03564470
• Other study ID #: PDT-Ph-Like
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: February 14, 2016
• Est. completion date: August 30, 2023

Study information

• Verified date: June 2022
• Source: Nanfang Hospital of Southern Medical University
• Contact: Hongshengq Zhou, MD, Ph.D
• Phone: 86-20-62787349
• Email: zhs1[@]i.smu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, two-arm, multi-site trial PDT-Ph-like-ALL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide and dasatinib for adult Ph-like ALL.

Description:

Ph-like, or BCR-ABL1-like lymphoblastic leukemia is neoplasm of lymphoblasts committed to the B-cell lineage that lack the BCR-ABL1 translocation but show a pattern of the expression very similar to that seen in BCR-ABL1-positive ALL. Chidamide is a novel oral HDACi with promising activity in non-Hodgkin lymphoma (NHL). Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, two-arm, multi-site trial is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor (HDACi) chidamide and tyrosine kinase inhibitor (TKI) dasatinib for adult Ph-like ALL/LBL. HDACi chidamide and TKI dasatinib will be added to chidamide and dasatinib group, respectively, from induction therapy to consolidation therapy (total courses of chidamide treatment: 5 courses for allo-HSCT after Consolidation Module-3; 12 courses for patients non-allo-HSCT after Consolidation Module 1-9). Primary study endpoint is event-free survival and secondary study endpoints are complete remission and MRD after induction, adverse event and overall survival. Pretreatment: Dexamethasone, -3 to 0d; Chidamide for chidamide arm: 10mg/d, po qd. Dasatinib for Dasatinib arm: 100mg/d, po qd. Induction:VCR: 1, 8, 15, 22; IDA: 1, 8; CTX: 1g/m2, 1; PEG-asp: 2000-2500IU/m2, 1, 15; Pred: 1-24; MRD assessment: d14, 24, 45, and pre-allo-HSCT. VLCAM (MRD1/d14>1%): CTX, d25; AraC 50mg/m2, d25-31, 26; 6-MP: 25-31, PEG-asp: 26; Consolidation Module: CM1: AraC 2g/m2, q12h, 1-2, Dex: 10mg/m2, 1-2, PEG-asp: 2, 6-MP: 1-7. IT: d1; CM2: MTX 3g/m2, 1, Dex: 10mg/m2, 1-2, PEG-asp: 2; 6-MP: 1-7; IT: d1; CM3: CTX 0.5g/m2, 1-3, PEG-asp: 2, 6-MP: 1-7, IT: d1. Allo-HSCT: after CM3 when donors available. Non-HSCT: finish CM 4-9 and POMP maintenance. CM4-6: repeat CM1-3. Re-Induction: after CM6. CM7-9: repeat CM1-3. Maintenance: POMP-Pred: x12m; VCR x12m; MTX: x24m; 6-MPx24m.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: August 30, 2023
• Est. primary completion date: August 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 55 Years

Eligibility

Inclusion Criteria:

• 14-55 years old;
• Ph-like ALL newly diagnosed;
• signed written informed consent

Exclusion Criteria:

• Pregnant women;
• History of pancreatitis;
• History of diabetes;
• History of active peptic ulcer disease in the past 6 months;
• History of arteriovenous thrombosis in the past 6 months;
• Severe active infection;
• Allergic to any drugs in PDT-Ph-like-ALL.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Acute
• Leukemia, B-cell
• Leukemia, Lymphoblastic
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• Chidamide
Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping,FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
• Dasatinib
Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping,FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.

Locations

Country	Name	City	State
China	Department of Hematology, Nanfang Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Nanfang Hospital of Southern Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Event free survival	EFS of Ph-like ALL group	3 years
Secondary	Minimum residual disease after induction	MRD after 1 course	3 months
Secondary	CR after Induction Therapy	CR rate of Ph-like group	3 months
Secondary	Death in induction		3 months
Secondary	Adverse events	AE during PDT-Ph-like	3 years
Secondary	Relapse	Relapse of Ph-like ALL	3 years
Secondary	Relapse free survival	RFS	3 years
Secondary	Overall survival	OS	3 years